Disclaimer: For the use of registered Medical practitioner or research lab
Clinical Trials were conducted at (Government Medical College & Government General Hospital, Hudco Colony, Balaga, Srikakulam, A. P. 532001)
Evaluation parameters
Study title
A double blind, placebo controlled, randomized clinical trial to evaluate the efficacy and safety of the Virulina® along with standard treatment as per hospital protocol for the treatment of novel coronavirus (COVID-19).
Study Objective
The primary objective was to assess the clinical efficacy of the Virulina® along with standard treatment as per hospital protocol for the treatment of novel coronavirus (COVID-19).
The secondary objective was to assess the clinical safety of the Virulina® along with standard treatment as per hospital protocol for the treatment of novel coronavirus (COVID-19).
Study Phase
Proof of effectiveness study
Study Design
Type: Interventional
Endpoint : Efficacy /safety
Primary Purpose: efficacy
Study: Double blind
Control: Placebo
Number of subjects
30
Patient disposition
30 eligible patients were randomly assigned to the two treatment groups in 1:1 ratio (15 subjects in each group).
Follow up period
14 days after last day of treatment
Human Trials reports that:
- In conclusion, the Virulina® with standard treatment is effective in virological and clinical cure of symptoms when compared to Placebo + Standard treatment group. It also reduces the inflammation and increases the Immune parameters when compared to control group.
- There were no adverse events reported.
- The group reduced the home care isolation time, medical consultations and hospital admissions. It also improved the subjective assessment of symptoms and subject perception scores were excellent. 93.33% of Virulina® treated patients were virologically and clinically cured compared to 53.33% in the placebo group.
- 93.33 % patients had nil symptoms of cough, fever, shortness of breath, chest congestion, nasal congestion, Diarrhoea, Other GI symptoms, Anosmia, Ageusia, fatigue, Neuro disorders, Myalgia, sleep disorder, Rhinorrhea, Expectoration, sore throat and vomiting after treatment with Virulina® and standard treatment group.
- 93.33% of patients were showing improvement in pulmonary results in chest x-ray of Virulina® with when compared to 46.67% of patients treated with Placebo
The oxygen saturation was improved significantly from 94.2 to 97.4 with Virulina®.
- Reduction of hospital admissions were seen in Virulina® when compared to Placebo treatment group.
- Reduction of Medical consultations needed after discharge by the subjects were seen in Virulina®
* For any further information please write to us on email: info@virulina.com